Eledon Pharmaceuticals, Inc. (ELDN)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-13) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-19) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-14) · 99.1 | 8-K (2025-11-07) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-Q | Q2-2025 | 8-K (2025-08-14) · 99.1 | ||
| 10-Q/A | Q1-2025 | |||
| 10-Q | Q1-2025 | 8-K (2025-05-14) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-20) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q/A | Q1-2024 | |||
| 10-Q | Q2-2024 | 8-K (2024-08-14) · 99.1 | ||
| 10-K/A | FY-2023 | |||
| 10-Q | Q1-2024 | 8-K (2024-05-13) · 99.1 | ||
| 10-K/A | FY-2023 | |||
| 10-K | FY-2023 | 8-K (2024-03-28) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-10) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Condensed Consolidated Statements of Operations | — |
|
| Condensed Consolidated Statements of Operations and Comprehensive Income (loss) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Comprehensive Income (loss) | — |
|
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity | — |
|
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (deficit) | — |
|
| Consolidated Statements of Convertible Stock and Stockholders' Equity | — |
|
| Consolidated Statements of Stockholders' Equity | ||
| Condensed Consolidated Statements of Stockholders' Equity (deficit) | — |
|
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued Expenses and Other Liabilities | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Description of Business | ||
| Fair Value Measurements | ||
| Going Concern and Management's Plans | ||
| Goodwill | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Net Income (loss) Per Share | — |
|
| Net Income/loss Per Share | — |
|
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Preferred Stock and Stockholders' Equity | ||
| Prepaid Expenses and Other Current Assets | ||
| Prepaid Expenses, Other Assets, Accrued Expenses and Other Liabilities | — |
|
| Restatement of Previously Issued Consolidated Financial Statements | — |
|
| Restatement of Previously Issued Financial Statements | — |
|
| Segment Reporting | — |
|
| Short-term Investments | ||
| Stock-based Compensation | ||
| Stockholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||